MEMPHIS, Tenn., Feb. 2 /PRNewswire-FirstCall/ -- GTx, Inc. , the Men’s Health Biotech Company, today announced that it will host a conference call and webcast to discuss the Company’s fourth quarter and year end 2005 financial results on Thursday, February 16 at 9:00 a.m., Eastern Time. The call and webcast will follow the release of the fourth quarter and year end 2005 financial results earlier that day.
To listen to the conference call, please dial: * 866-277-1184 from the United States and Canada or * 617-597-5360 (International) The access code for the call is 54502054.
A playback of the call will be available from approximately 11:00 a.m., Eastern Time, on February 16 through March 2 and may be accessed by dialing:
* 888-286-8010 from the United States and Canada or * 617-801-6888 (International) The reservation number for the replay is 64277344.
Additionally, you may access the live and subsequently archived webcast of the conference call from the Investor Relations section of the Company’s website at http://www.gtxinc.com.
About GTx
GTx is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for cancer and serious conditions related to men’s health. GTx’s lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. GTx, headquartered in Memphis, Tenn., currently has four clinical programs. GTx is developing ACAPODENE (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: (1) a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer and (2) a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade PIN. In its third clinical program, GTx is developing ostarine for the treatment of wasting associated with burns. GTx is also evaluating clinical development of ostarine for the treatment of other muscle wasting conditions. In its fourth clinical program, GTx and its partner, Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, are developing andarine, another of GTx’s SARMs, for the treatment of cancer cachexia. GTx is working with Ortho Biotech to plan a Phase II clinical trial of andarine.
GTx, Inc.
CONTACT: McDavid Stilwell, Manager, Corporate Communications and FinancialAnalysis of GTx, Inc., +1-901-523-9700
Web site: http://www.gtxinc.com/
